NexgenRx Statistics

Total Valuation

NexgenRx has a market cap or net worth of CAD 19.20 million. The enterprise value is 19.48 million.

Market Cap	19.20M
Enterprise Value	19.48M

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

NexgenRx has 71.12 million shares outstanding. The number of shares has increased by 0.98% in one year.

Current Share Class	n/a
Shares Outstanding	71.12M
Shares Change (YoY)	+0.98%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	37.18%
Owned by Institutions (%)	n/a
Float	44.38M

Valuation Ratios

The trailing PE ratio is 82.02.

PE Ratio	82.02
Forward PE	n/a
PS Ratio	1.19
PB Ratio	2.98
P/TBV Ratio	7.12
P/FCF Ratio	15.51
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.43, with an EV/FCF ratio of 15.73.

EV / Earnings	76.52
EV / Sales	1.21
EV / EBITDA	11.43
EV / EBIT	40.59
EV / FCF	15.73

Financial Position

The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.06.

Current Ratio	1.09
Quick Ratio	0.13
Debt / Equity	0.06
Debt / EBITDA	0.27
Debt / FCF	0.38
Interest Coverage	7.29

Financial Efficiency

Return on equity (ROE) is 3.06% and return on invested capital (ROIC) is 3.43%.

Return on Equity (ROE)	3.06%
Return on Assets (ROA)	0.98%
Return on Invested Capital (ROIC)	3.43%
Return on Capital Employed (ROCE)	5.65%
Revenue Per Employee	805,499
Profits Per Employee	12,726
Employee Count	20
Asset Turnover	0.53
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.00% in the last 52 weeks. The beta is 0.37, so NexgenRx's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+8.00%
50-Day Moving Average	0.27
200-Day Moving Average	0.27
Relative Strength Index (RSI)	50.51
Average Volume (20 Days)	37,335

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NexgenRx had revenue of CAD 16.11 million and earned 254,524 in profits. Earnings per share was 0.00.

Revenue	16.11M
Gross Profit	12.50M
Operating Income	479,752
Pretax Income	279,954
Net Income	254,524
EBITDA	1.63M
EBIT	479,752
Earnings Per Share (EPS)	0.00

Full Income Statement

Balance Sheet

The company has 1.84 million in cash and 468,544 in debt, giving a net cash position of 1.38 million or 0.02 per share.

Cash & Cash Equivalents	1.84M
Total Debt	468,544
Net Cash	1.38M
Net Cash Per Share	0.02
Equity (Book Value)	8.10M
Book Value Per Share	0.09
Working Capital	2.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.31 million and capital expenditures -68,811, giving a free cash flow of 1.24 million.

Operating Cash Flow	1.31M
Capital Expenditures	-68,811
Free Cash Flow	1.24M
FCF Per Share	0.02

Full Cash Flow Statement

Margins

Gross margin is 77.58%, with operating and profit margins of 2.98% and 1.58%.

Gross Margin	77.58%
Operating Margin	2.98%
Pretax Margin	1.74%
Profit Margin	1.58%
EBITDA Margin	10.09%
EBIT Margin	2.98%
FCF Margin	7.68%

Dividends & Yields

This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 3.70%.

Dividend Per Share	0.01
Dividend Yield	3.70%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	481.26%
Buyback Yield	-0.98%
Shareholder Yield	2.73%
Earnings Yield	1.33%
FCF Yield	6.45%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NexgenRx has an Altman Z-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1
Piotroski F-Score	n/a